Results 61 to 70 of about 269,068 (254)

Chinese expert consensus on precision diagnosis, treatment, and multidisciplinary management of immune platelet transfusion refractoriness (2026 Edition)

Zhongguo shuxue zazhi
Patients with thrombocytopenia or platelet dysfunction often require platelet transfusions to improve their condition. However, some patients develop platelet transfusion refractoriness (PTR) after multiple transfusions, characterized by a lack of ...
Clinical Transfusion Medicine Professional Committee of the Chinese Society of Blood Transfusion
doaj   +1 more source

Analysis of HLA allele-specific antibodies and Eplets in patients with platelet transfusion refractoriness

, 2022
Objective To analyze the specificity and Eplets of HLA allele-specific antibody in patients with platelet transfusion refractoriness (PTR). Methods HLA-A and B genotypes were detected by PCR-SBT, and HLA-Ⅰ antibodies in patients′ serum were detected by ...
Xinyu HUANG, Ying LIU, Faming ZHU, Gang XU, Bing ZHANG, Xianguo XU, Shu CHEN   +6 more
core   +1 more source

Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Pediatric Investigation, EarlyView.
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin   +12 more
wiley   +1 more source

Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care

Pediatric Investigation, EarlyView.
This review presents a bedside framework for recognizing pediatric hemophagocytic lymphohistiocytosis and cytokine storm, stabilizing organ dysfunction, identifying the underlying phenotype, selecting targeted immunomodulation, considering extracorporeal adjuncts, and reassessing response within 24–72 h. ABSTRACT Hemophagocytic lymphohistiocytosis (HLH)
Weerapong Lilitwat, Prakreeti Bhandari
wiley   +1 more source

Preclinical Efficacy and Safety Evaluation of a Novel Controlled‐Expansion ePTFE‐Covered TIPS Stent in a Swine Model

Portal Hypertension &Cirrhosis, EarlyView.
This preclinical study evaluated a novel controlled‐expansion expanded polytetrafluoroethylene (ePTFE)‐covered transjugular intrahepatic portosystemic shunt (TIPS) stent in 11 swine, demonstrating 100% technical success, excellent deployability, and durable 6‐month angiographic patency without thrombosis, migration, fracture, or device‐related toxicity.
Yi Xiang, Qi Zhang, Chuan Liu, Jiawei Zhang, Qingqiao Zhang, Changsheng Shi, Chunze Zhou, Yudong Zhang, Hongliang He, Hao Xie, Hui Shi, Haijian Guo, Wenjing Liu, Muqing Lin, Huajie Yu, Xiaolong Qi   +15 more
wiley   +1 more source

Research progress on the pathogenesis, prevention and treatment of immune platelet transfusion refractoriness

Zhongguo shuxue zazhi
Platelet transfusion refractoriness (PTR) is one of the common problems in platelet transfusion, significantly impacting patient clinical outcomes and increasing the demand for allogeneic platelet transfusion.
LI Penghui, WU Chenggao, LE Aiping
doaj   +1 more source

Refractoriness to platelet transfusion after single-donor consecutive platelet transfusions and its relationship to platelet antibodies [PDF]

Journal of Korean Medical Science, 1988
In thirty patients with acute leukemia and severe aplastic anemia receiving random single donor platelet transfusions, the development of refractoriness by consecutive platelet transfusions with cytapheresis and its relationship to the appearance of anti-platelet antibodies were investigated.
M, Lee, B K, Kim, S, Park, C, Suh, M H, Park, M J, Cho   +5 more
openaire   +2 more sources

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Nonthermal plasma approaches for combating implant‐associated infections: A compendious review

VIEW, EarlyView.
Implant‐associated infections pose serious clinical challenges. Non‐thermal plasma (NTP) modifications overcome this bottleneck in distinct ways relative to traditional sterilization methods. Gas‐phase plasmas generate highly energetic species, UV radiation and reactive oxygen/nitrogen species (RONS), which alter the implant surface properties.
A. M. Trimukhe, Satish Rojekar, Amol Gholap, K. Navaneetha Pandiyaraj, Mukesh Patekar, Claudia Riccardi, R. R. Deshmukh, Tomáš Kovářík, Kalim Deshmukh   +8 more
wiley   +1 more source

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation

Haematologica, 2018
HLA antibodies are associated with refractoriness to platelet transfusion, leading to rapid platelet clearance, sometimes coinciding with clinical side effects such as fever and chills.
Maaike Rijkers, Anno Saris, Sebastiaan Heidt, Arend Mulder, Leendert Porcelijn, Frans H.J. Claas, Ruben Bierings, Frank W.G. Leebeek, A.J. Gerard Jansen, Gestur Vidarsson, Jan Voorberg, Masja de Haas   +11 more
doaj   +1 more source